The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)

Taking the patient off osimertinib is indicated (PMID 31882494) plus corticosteroid therapy.

Publications

Lin Z, Wu L, Yu Y, Jiang J, Yang Y, Xiao G

Case Report: Osimertinib-induced acute interstitial lung disease.

Frontiers in pharmacology. 2025;16:1608733

Possick JD

Welcome to the Real World: Understanding the Many Faces of Osimertinib-Related Pneumonitis.

Chest. 2022;162(5):965-967

Le Guen Y, Lederlin M, Triquet L, Lesouhaitier M, Le Tulzo Y, Ricordel C

[Pulmonary manifestations induced by osimertinib].

Revue des maladies respiratoires. 2022;39(1):62-66

Kodama H, Wakuda K, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi T

Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.

Investigational new drugs. 2021;39(2):571-577

Lu H, Dowell J

Osimertinib in Pulmonary Manifestations: Two Case Reports and Review of the Literature.

In vivo (Athens, Greece). 2020;34(1):315-319

Fan M, Mo T, Shen L, Yang L

Osimertinib-induced severe interstitial lung disease: A case report.

Thoracic cancer. 2019;10(7):1657-1660

Deng SM, Huang JA, Chen YB

Fatal interstitial lung disease associated with AZD9291.

Journal of cancer research and therapeutics. 2018;14(Supplement):S1227-S1229

Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(12):1288-1296